search
Back to results

A Clinical Study to Access the Pharmacokinetics of HMS5552 in Hepatic Impaired Subjects and Healthy Volunteers

Primary Purpose

Type 2 Diabetes Mellitus

Status
Completed
Phase
Phase 1
Locations
China
Study Type
Interventional
Intervention
HMS5552
Sponsored by
Hua Medicine Limited
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Type 2 Diabetes Mellitus

Eligibility Criteria

18 Years - 65 Years (Adult, Older Adult)All SexesAccepts Healthy Volunteers

Inclusion Criteria:

  • For hepatic impaired subjects:

    1. Male and female subjects between ages of 18 and 65 years, no less than 3 subjects in each gender.
    2. Body weight≥50kg for male and ≥45kg for female; BMI: 18.5~30 kg/m2
    3. ALT>2×normal upper limit (ULN), or TBiL>1.5×ULN, or diagnosed cirrhosis. The related clinical manifestations have been stable for 4-12 weeks, and Child-Pugh score is in grade A or B:

      A= mild liver damage (Group A): Child-Pugh 5-6; B= moderate liver damage (Group B): Child-Pugh 7-9;

    4. Willing to sign the informed consent form (ICF) and take reliable contraceptive measures within 6 months after taking the last dose of study drug;
    5. Willing to adhere to the protocol requirement.
  • For healthy volunteers:

    1. Male and female subjects between ages of 18 and 65 years, no less than 3 subjects in each gender;
    2. Body weight≥50kg for male and ≥45kg for female; BMI: 18.5~30 kg/m2;
    3. Gender, age (±5 years) and BMI (±15%) matched with corresponding subject in hepatic impaired group;
    4. Normal physical conditions, vital signs,12 lead ECG and laboratory recording;
    5. Willing to sign the informed consent form (ICF) and take reliable contraceptive measures within 6 months after taking the last dose of study drug;
    6. Willing to adhere to the protocol requirement.

Exclusion Criteria:

  • Subjects with impaired hepatic function cannot be enrolled if they meet one of the following criteria:

    1. Liver cancer, liver transplantation, liver failure, autoimmune liver disease, biliary cirrhosis, or drug-induced liver damage;
    2. History of allergy;
    3. Investigators adjudicate subjects have surgery that may affect drug absorption, distribution, metabolism or excretion;
    4. In addition to diseases and complications of impaired hepatic function, investigator adjudicate subjects have clinically meaningful or unstable diseases or complications of central nervous system, cardiovascular system, digestive system, endocrine system, respiratory system, urinary system, blood system, mental disease, or malignant tumor, etc;
    5. Abnormal of ECG performance or laboratory recording during screening;
    6. Family history of QT prolongation syndrome;
    7. History of hepatic encephalopathy or hepatic coma within 6 months before screening;
    8. More than 5 cigarettes per day within 3 months before screening;
    9. Alcohol addicts;
    10. History of drug abuse
  • Healthy subjects cannot be enrolled if they meet one of the following criteria:

    1. History of allergy;
    2. Investigators adjudicate subjects have surgery that may affect drug absorption, distribution, metabolism or excretion;
    3. Investigator adjudicate subjects have clinically meaningful or unstable diseases or complications of central nervous system, cardiovascular system, digestive system, endocrine system, respiratory system, urinary system, blood system, mental disease, or malignant tumor, etc;
    4. Abnormal of ECG performance or laboratory recording during screening;
    5. Family history of QT prolongation syndrome;
    6. Severe infection, severe trauma or major surgery judged by investigator within 3 months before screening;
    7. More than 5 cigarettes per day within 3 months before screening;
    8. Alcohol addicts;
    9. History of drug abuse

Sites / Locations

  • West China Hospital of Sichuan University

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm Type

Experimental

Experimental

Experimental

Arm Label

Mild hepatic impaired subjects (A)

Moderate hepatic impaired subjects (B)

Healthy volunteers (C)

Arm Description

Mild hepatic impaired subjects: to receive a single dose of HMS5552 ( 25mg ) tablet orally

Moderate hepatic impaired subjects: to receive a single dose of HMS5552 ( 25mg ) tablet orally

Matched healthy volunteers: to receive a single dose of HMS5552 ( 25mg ) tablet orally

Outcomes

Primary Outcome Measures

The single dose pharmacokinetics of HMS5552 will be described by estimating parameters of Cmax;
Plasma will be collected at predose, 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 36, 48 and 72 hour post-dose.
The single dose pharmacokinetics of HMS5552 will be described by estimating parameters of AUClast;
Plasma will be collected at predose, 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 36, 48 and 72 hour post-dose.
The single dose pharmacokinetics of HMS5552 will be described by estimating parameters of AUCinf;
Plasma will be collected at predose, 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 36, 48 and 72 hour post-dose.

Secondary Outcome Measures

The single dose pharmacokinetics of HMS5552 will be described by estimating parameters of Cmax,u
Plasma will be collected at predose, 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 36, 48 and 72 hour post-dose.
The single dose pharmacokinetics of HMS5552 will be described by estimating parameters of AUClast,u
Plasma will be collected at predose, 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 36, 48 and 72 hour post-dose.
The single dose pharmacokinetics of HMS5552 will be described by estimating parameters of AUCinf,u
Plasma will be collected at predose, 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 36, 48 and 72 hour post-dose.
The single dose pharmacokinetics of HMS5552 will be described by estimating parameters of Tmax ;
Plasma will be collected at predose, 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 36, 48 and 72 hour post-dose.
The single dose pharmacokinetics of HMS5552 will be described by estimating parameters of T1/2;
Plasma will be collected at predose, 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 36, 48 and 72 hour post-dose.
The single dose pharmacokinetics of HMS5552 will be described by estimating parameters of CL/F;
Plasma will be collected at predose, 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 36, 48 and 72 hour post-dose.
The single dose pharmacokinetics of HMS5552 will be described by estimating parameters of Vz/F;
Plasma will be collected at predose, 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 36, 48 and 72 hour post-dose.
The single dose pharmacokinetics of HMS5552 will be described by estimating parameters of fu;
Plasma will be collected at predose, 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 36, 48 and 72 hour post-dose.

Full Information

First Posted
June 8, 2020
Last Updated
November 28, 2022
Sponsor
Hua Medicine Limited
search

1. Study Identification

Unique Protocol Identification Number
NCT04426708
Brief Title
A Clinical Study to Access the Pharmacokinetics of HMS5552 in Hepatic Impaired Subjects and Healthy Volunteers
Official Title
An Open-Label, Paralleled Study of the Pharmacokinetics of HMS5552 Following a Single Oral Dose in Mild and Moderate Hepatic Impaired Subjects and Matched Healthy Volunteers
Study Type
Interventional

2. Study Status

Record Verification Date
June 2020
Overall Recruitment Status
Completed
Study Start Date
February 18, 2019 (Actual)
Primary Completion Date
July 3, 2020 (Actual)
Study Completion Date
July 3, 2020 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Hua Medicine Limited

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
The objectives of this study is to access the pharmacokinetics and safety of HMS5552 in single dose in mild and moderate hepatic impaired subjects and matched healthy adult subjects.
Detailed Description
This is an open-label and paralleled study with single oral dose of HMS5552 given to hepatic impaired subjects and matched healthy volunteers. The primary objective is to access the pharmacokinetic profiles of HMS5552 in 25 mg dose in hepatic impaired subjects and (gender, age and BMI) matched healthy adult subjects. The secondary objective is to characterize the safety profiles of HMS5552 in single dose in hepatic impaired subjects. The subjects include mild hepatic impaired subjects (A group), moderate hepatic impaired subjects (B group), and healthy subjects (C Group) matched with hepatic impaired subjects in gender, age and BMI. The number of subjects in each group was no less than 8, and no less than 3 subjects in each gender.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Type 2 Diabetes Mellitus

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 1
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Non-Randomized
Enrollment
25 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Mild hepatic impaired subjects (A)
Arm Type
Experimental
Arm Description
Mild hepatic impaired subjects: to receive a single dose of HMS5552 ( 25mg ) tablet orally
Arm Title
Moderate hepatic impaired subjects (B)
Arm Type
Experimental
Arm Description
Moderate hepatic impaired subjects: to receive a single dose of HMS5552 ( 25mg ) tablet orally
Arm Title
Healthy volunteers (C)
Arm Type
Experimental
Arm Description
Matched healthy volunteers: to receive a single dose of HMS5552 ( 25mg ) tablet orally
Intervention Type
Drug
Intervention Name(s)
HMS5552
Intervention Description
single dose of HMS5552 25mg
Primary Outcome Measure Information:
Title
The single dose pharmacokinetics of HMS5552 will be described by estimating parameters of Cmax;
Description
Plasma will be collected at predose, 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 36, 48 and 72 hour post-dose.
Time Frame
Up to 72 hours post-dose
Title
The single dose pharmacokinetics of HMS5552 will be described by estimating parameters of AUClast;
Description
Plasma will be collected at predose, 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 36, 48 and 72 hour post-dose.
Time Frame
Up to 72 hours post-dose
Title
The single dose pharmacokinetics of HMS5552 will be described by estimating parameters of AUCinf;
Description
Plasma will be collected at predose, 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 36, 48 and 72 hour post-dose.
Time Frame
Up to 72 hours post-dose
Secondary Outcome Measure Information:
Title
The single dose pharmacokinetics of HMS5552 will be described by estimating parameters of Cmax,u
Description
Plasma will be collected at predose, 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 36, 48 and 72 hour post-dose.
Time Frame
Up to 72 hours post-dose
Title
The single dose pharmacokinetics of HMS5552 will be described by estimating parameters of AUClast,u
Description
Plasma will be collected at predose, 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 36, 48 and 72 hour post-dose.
Time Frame
Up to 72 hours post-dose
Title
The single dose pharmacokinetics of HMS5552 will be described by estimating parameters of AUCinf,u
Description
Plasma will be collected at predose, 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 36, 48 and 72 hour post-dose.
Time Frame
Up to 72 hours post-dose
Title
The single dose pharmacokinetics of HMS5552 will be described by estimating parameters of Tmax ;
Description
Plasma will be collected at predose, 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 36, 48 and 72 hour post-dose.
Time Frame
Up to 72 hours post-dose
Title
The single dose pharmacokinetics of HMS5552 will be described by estimating parameters of T1/2;
Description
Plasma will be collected at predose, 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 36, 48 and 72 hour post-dose.
Time Frame
Up to 72 hours post-dose
Title
The single dose pharmacokinetics of HMS5552 will be described by estimating parameters of CL/F;
Description
Plasma will be collected at predose, 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 36, 48 and 72 hour post-dose.
Time Frame
Up to 72 hours post-dose
Title
The single dose pharmacokinetics of HMS5552 will be described by estimating parameters of Vz/F;
Description
Plasma will be collected at predose, 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 36, 48 and 72 hour post-dose.
Time Frame
Up to 72 hours post-dose
Title
The single dose pharmacokinetics of HMS5552 will be described by estimating parameters of fu;
Description
Plasma will be collected at predose, 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 36, 48 and 72 hour post-dose.
Time Frame
Up to 72 hours post-dose

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
65 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: For hepatic impaired subjects: Male and female subjects between ages of 18 and 65 years, no less than 3 subjects in each gender. Body weight≥50kg for male and ≥45kg for female; BMI: 18.5~30 kg/m2 ALT>2×normal upper limit (ULN), or TBiL>1.5×ULN, or diagnosed cirrhosis. The related clinical manifestations have been stable for 4-12 weeks, and Child-Pugh score is in grade A or B: A= mild liver damage (Group A): Child-Pugh 5-6; B= moderate liver damage (Group B): Child-Pugh 7-9; Willing to sign the informed consent form (ICF) and take reliable contraceptive measures within 6 months after taking the last dose of study drug; Willing to adhere to the protocol requirement. For healthy volunteers: Male and female subjects between ages of 18 and 65 years, no less than 3 subjects in each gender; Body weight≥50kg for male and ≥45kg for female; BMI: 18.5~30 kg/m2; Gender, age (±5 years) and BMI (±15%) matched with corresponding subject in hepatic impaired group; Normal physical conditions, vital signs,12 lead ECG and laboratory recording; Willing to sign the informed consent form (ICF) and take reliable contraceptive measures within 6 months after taking the last dose of study drug; Willing to adhere to the protocol requirement. Exclusion Criteria: Subjects with impaired hepatic function cannot be enrolled if they meet one of the following criteria: Liver cancer, liver transplantation, liver failure, autoimmune liver disease, biliary cirrhosis, or drug-induced liver damage; History of allergy; Investigators adjudicate subjects have surgery that may affect drug absorption, distribution, metabolism or excretion; In addition to diseases and complications of impaired hepatic function, investigator adjudicate subjects have clinically meaningful or unstable diseases or complications of central nervous system, cardiovascular system, digestive system, endocrine system, respiratory system, urinary system, blood system, mental disease, or malignant tumor, etc; Abnormal of ECG performance or laboratory recording during screening; Family history of QT prolongation syndrome; History of hepatic encephalopathy or hepatic coma within 6 months before screening; More than 5 cigarettes per day within 3 months before screening; Alcohol addicts; History of drug abuse Healthy subjects cannot be enrolled if they meet one of the following criteria: History of allergy; Investigators adjudicate subjects have surgery that may affect drug absorption, distribution, metabolism or excretion; Investigator adjudicate subjects have clinically meaningful or unstable diseases or complications of central nervous system, cardiovascular system, digestive system, endocrine system, respiratory system, urinary system, blood system, mental disease, or malignant tumor, etc; Abnormal of ECG performance or laboratory recording during screening; Family history of QT prolongation syndrome; Severe infection, severe trauma or major surgery judged by investigator within 3 months before screening; More than 5 cigarettes per day within 3 months before screening; Alcohol addicts; History of drug abuse
Facility Information:
Facility Name
West China Hospital of Sichuan University
City
Chengdu
State/Province
Sichuan
ZIP/Postal Code
610000
Country
China

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

A Clinical Study to Access the Pharmacokinetics of HMS5552 in Hepatic Impaired Subjects and Healthy Volunteers

We'll reach out to this number within 24 hrs